Skip to content

Imaging Procedure

PROCEDURE10 trials

Sponsors

Assistance Publique - Hôpitaux de Paris, OHSU Knight Cancer Institute, NRG Oncology, University College, London, National Cancer Institute (NCI)

Conditions

Acute Myeloid Leukemia Post Cytotoxic TherapyAdvanced Hepatocellular CarcinomaAdvanced NUT CarcinomaCutaneous MelanomaLow Grade Fallopian Tube Serous AdenocarcinomaMelanocytic NevusMetastatic Hepatocellular CarcinomaMetastatic NUT Carcinoma

Phase 1

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
SuspendedNCT04539366
National Cancer Institute (NCI)Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma +5
Start: 2022-01-25End: 2040-12-31Target: 67Updated: 2025-11-03
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
RecruitingNCT05019716
National Cancer Institute (NCI)Advanced NUT Carcinoma, Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Start: 2022-07-13End: 2026-06-30Target: 36Updated: 2026-04-03
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RecruitingNCT06811116
National Cancer Institute (NCI)Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 +1
Start: 2025-11-17End: 2027-08-31Target: 92Updated: 2026-04-03
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Not yet recruitingNCT07012044
National Cancer Institute (NCI)Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Start: 2026-10-30End: 2027-01-01Target: 47Updated: 2026-04-03

Phase 2

Phase 3

Unknown Phase

Related Papers